Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oncternal Therapeutics (ONCT – Research Report), ICU Medical (ICUI – Research Report) and Enanta Pharmaceuticals (ENTA – Research Report). Oncternal Therapeutics (ONCT) Maxim Group analyst Naureen Quibria initiated coverage with a Buy rating on Oncternal Therapeutics today and set a price target of $3.50. The company's shares closed last Monday at $0.99, close to its 52-week low of $0.85. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-oncternal-therapeutics-onct-icu-medical-icui-and-enanta-pharmaceuticals-enta?utm_source=advfn.com&utm_medium=referral
Oncternal Therapeutics (NASDAQ:ONCT)
Gráfico Histórico do Ativo
De Jun 2022 até Jul 2022 Click aqui para mais gráficos Oncternal Therapeutics.
Oncternal Therapeutics (NASDAQ:ONCT)
Gráfico Histórico do Ativo
De Jul 2021 até Jul 2022 Click aqui para mais gráficos Oncternal Therapeutics.